Abstract
Anxiety disorders are characterized by an excessive fear response; these disorders are extremely prevalent among the general population and have a 2:1 female predilection [1]. Functional impairment is common with these disorders and, along with depression, are among the leading causes of disability and work related absences. As such, it is postulated that the economic burden of anxiety disorders is greater than any other psychiatric disorder due to the high prevalence and cost of medical and psychiatric treatment [2]. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), defines fear as “the emotional response to real or perceived imminent threat” and anxiety as “anticipation of future threat.” Fear typically induces surges of autonomic arousal and thoughts of immediate danger and escape, whereas anxiety typically manifests as muscular tension and avoidant behaviors. If the anxiety creates maladaptive behaviors, physical manifestations, or mental symptoms then it becomes problematic. The anxiety disorders listed in the DSM-5 tend to be highly comorbid with other psychiatric conditions [1]. Anxiety disorders discussed in this chapter are the following: separation anxiety disorder, selective mutism, specific phobia, social anxiety disorder, panic disorder, agoraphobia, and general anxiety disorder. Other anxiety disorders that do not fall under the previously mentioned disorders will briefly be discussed. In addition, obsessive-compulsive, trauma- and stress-induced related disorders will be discussed due to their relevance to anxiety. Anxiety disorders covered in this chapter are presented in Table 1 with associated ages of onset.
Similar content being viewed by others
References
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Association; 2013. p. 607–913.
Garakani A, Murrough J, Iosifescu D. Advances in psychopharmacology for anxiety disorders. Focus. 2014;XII(2):152–62.
Allgulander C. Morbid anxiety as a risk factor in patients with somatic diseases: a review of recent findings. Mind Brain. 2010;1:11–9.
Mohatt J, Bennett S, Walkup J. Treatment of separation, generalized, and social anxiety disorders in youths. Am J Psychiatry. 2014;171:7.
Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593–602.
Angelosante AG, Ostrowski MA, Chizkov RR. Separation anxiety disorder. In: Vasa RA, Roy AK, editors. Pediatric anxiety disorders. New York: Springer Science; 2013. p. 129–42.
Manicavasagar V, Silove D, Wagner R, Drobny J. A self-report questionnaire for measuring separation anxiety in adulthood. Compr Psychiatry. 2003;44(2):146–53.
Lebowitz ER, Woolston J, Bar-Haim Y, et al. Family accommodation in pediatric anxiety disorders. Depress Anxiety. 2013;30(1):47–54.
Wong P. Selective mutism: a review of etiology, comorbidities, and treatment. Psychiatry. 2010;7(3):23–31.
Bandelow B. Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders. CNS Spectr. 2017;22(5):404–6.
Wittchen HU, Kessler RC, Beesdo K, et al. Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry. 2002;63(Suppl 8):24–34.
Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders ofthe brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21:655.
Lenze EJ. Anxiety disorders in the elderly. In: Stein DJ, Hollander E, Rothbaum BO, editors. Textbook of anxiety disorders, vol. 2. Washington, DC: American Psychiatric Publishing; 2010. p. 651.
Kessler RC, Gruber M, Hettema JM, et al. Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up. Psychol Med. 2008;38(3):365–74.
Scneider F, Milrod B. Gabbard’s treatments of psychiatric disorders. 5th ed. Arlington: American Psychiatric Publishing; 2014.
Grant JE, Odlaug BA, Won KS. N-Acetylcysteine, a glutamate modulator, in the treatment of Trichotillomania. Arch Gen Psychiatry. 2009;66(7):756–63.
Koran LM, Simpson HB. Guideline watch: practice guidelines for the treatment of patients with obsessive-compulsive disorder. APA Pract Guidel. 2013; 1–22.
Seim AR, Jozefiak T, Wichstrøm L, Kayed NS. Validity of reactive attachment disorder and disinhibited social engagement disorder in adolescence. Eur Child Adolesc Psychiatry. 2019;12:1–2.
Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50–5.
Koerner N, Antony M, Dugas M. Limitations of the Hamilton Anxiety Rating Scale as a primary outcome measure in randomized, controlled trials of treatments for generalized anxiety disorder. Am J Psychiatry. 2010;167(1):103–4.
Spitzer RL, Kroenke K, Willimas JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.
Ruiz MA, Zamorano E, García-Campayo J, et al. Validity of the GAD-7 scale as an outcome measure of disability in patients with generalized anxiety disorders in primary care. J Affect Disord. 2011;128(3):277–86.
Rickels K, Etemad B, Khalid-Khan S, et al. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. Arch Gen Psychiatry. 2010;67(12):1274–81.
Batterham PJ, Mackinnon AJ, Christensen H. The panic disorder screener (PADIS): development of an accurate and brief population screening tool. Psychiatry Res. 2015;228(1):72–6.
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737–44.
Cupp M. Pharmacotherapy of anxiety disorders. Prescriber’s Lett. 2014; PL Detail-Doc #301006: 1–5.
American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. Arlington: American Psychiatric Association Publishing; 2010.
Sarris J, Stough C, Bousman C. Kava in the treatment of generalized anxiety disorder: a double-blind,randomized, placebo-controlled study. J Clin Psychopharmacol. 2013;33(5):643–8.
Cuijpers P, Sijbrandij M, Koole S, Andersson G, Beekman A, Reynolds C. Adding psychotherapy toantidepressant medication in depression and anxiety disorders: a meta-analysis. Focus. 2014;XII(3):347–58.
Hoepner C. OTC agents for depression, anxiety, and insomnia. Carlat Rep Psychiatr. 2013;11(7):1–3.
Bezchlibnyk-Butler K, Jeffries J, Procyshyn R, Virani A. Anxiolytic agents. In: Clinical handbook of psychotropic drugs. 20th ed. Boston: Hogrefe Publishing; 2014. p. 196–212.
Dresler T, Guhn A, Tupak SV, et al. Revise the revised? New dimensions of the neuroanatomical hypothesis of panic disorder. J Neural Transm. 2013;120(1):3–29.
Cascade E, Kalali AH, Kennedy SH. Real-world data on SSRI antidepressant side effects. Psychiatry (Edgmont). 2009;6(2):16.
Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(Suppl 11):37–41.
Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013;202:396–7.
CNS Drugs: November 1997, Volume 8, Issue 5, pp 394–401.
de Abajo FJ, Rodríguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319(7217):1106–9.
Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352(11):1112–20.
Marangell LB. Switching antidepressants for treatment-resistant major depression. J Clin Psychiatry. 2001;62(Suppl 18):12–7.
Farach FJ, Pruitt LD, Jun JJ, et al. Pharmacological treatment of anxiety disorders: current treatments and future directions. J Anxiety Disord. 2012;26(8):833–43.
Kim S, Roth WT, Wollburg E. Effects of therapeutic relationship, expectancy, and credibility in breathing therapies for anxiety. Bull Menn Clin. 2015;79(2):116–30.
Pilkington K, Kirkwood G, Rampes H, Richardson J. Yoga for depression: the research evidence. J Affect Disord. 2005;89(1–3):13–24.
Kirkwood G, Rampes H, Tuffrey V, et al. Yoga for anxiety: a systematic review of the research evidence. Br J Sports Med. 2005;39(12):884–91.
Sharma M. Yoga as an alternative and complementary approach for stress management: a systematic review. J Evid Based Complementary Altern Med. 2014;19:59–67.
Biddle S. Physical activity and mental health: evidence is growing. World Psychiatry. 2016;15(2):176.
Aylett E, Small N, Bower P. Exercise in the treatment of clinical anxiety in general practice–a systematic review and meta-analysis. BMC Health Serv Res. 2018;18(1):559.
Stubbs B, Vancampfort D, Rosenbaum S, et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: a meta-analysis. Psychiatry Res. 2017;249:102–8.
Bazzan A, Zabrecky G, Monti D, Newberg A. Current evidence regarding the management of mood and anxiety disorders using complementary and alternative medicine. Neurotherapeutics. 2014;14(4):411–23.
Davis DM, Hayes JA. What are the benefits of mindfulness? A practice review of psychotherapy-related research. Psychotherapy. 2011;48(2):198.
Hofmann SG, Gómez AF. Mindfulness-based interventions for anxiety and depression. Psychiatr Clin. 2017;40(4):739–49.
Spijkerman MP, Pots WT, Bohlmeijer ET. Effectiveness of online mindfulness-based interventions in improving mental health: a review and meta-analysis of randomised controlled trials. Clin Psychol Rev. 2016;45:102–14.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 This is a U.S. Government work and not under copyright protection in the U.S.; foreign copyright protection may apply
About this entry
Cite this entry
Wilk, A., Garland, S., DeSilva, N. (2020). Anxiety Disorders. In: Paulman, P., Taylor, R., Paulman, A., Nasir, L. (eds) Family Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0779-3_166-1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0779-3_166-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-0779-3
Online ISBN: 978-1-4939-0779-3
eBook Packages: Springer Reference MedicineReference Module Medicine